ACADIA Pharmaceuticals Inc. (ACAD) Stock Analysis
Last updated Sep 8, 2026
Health Check
Last analyzed Sep 7, 2026
- Financial Health 70
- Profitability 85
- Business Quality 75
- Balance Sheet 65
- Cash Flow 80
Why this rating?
Health 75/100 — Elite Quality
Entry timing is weak right now. Quality may be fine; the setup is not.
Company overview
ACADIA Pharmaceuticals Inc. (ACAD) is a Biotechnology company in the Healthcare sector. Compound Radar rates ACADIA Pharmaceuticals Inc. 75/100 (Elite Quality) due to high business quality, strong revenue growth, and manageable leverage.
Investment profile
- Quality High
- Growth Strong
- Balance Sheet Adequate
- Valuation Fair
Financial highlights
Valuation
- P/E 12.37
- Forward P/E 30.99
- EV/Revenue 3.47
Profitability
- Revenue Growth 16.4%
- Gross Margin 62.1%
- Operating Margin 12.3%
- Net Margin 33.4%
- ROE 35.7%
Financial strength
- Cash $956.47M
- Debt $73.85M
- Net Cash $882.62M
- Free Cash Flow $105.15M
- Current Ratio 3.39
Similar companies
Peers in Biotechnology, ranked by Financial Health.
Latest quoted price for the name. Helps anchor the setup in today’s market level.
Health Entry- Aurinia Pharmaceuticals Inc. Biotechnology AUPH$16.07 83 Health 83 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Watch WatchWorth tracking, but timing is mixed — not a clear setup yet.
- Incyte Corporation Biotechnology INCY$124.40 82 Health 82 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Watch WatchWorth tracking, but timing is mixed — not a clear setup yet.
- Catalyst Pharmaceuticals Inc Biotechnology CPRX$31.49 81 Health 81 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Watch WatchWorth tracking, but timing is mixed — not a clear setup yet.
- Alnylam Pharmaceuticals, Inc. Biotechnology ALNY$260.10 78 Health 78 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Halozyme Therapeutics, Inc. Biotechnology HALO$108.31 77 Health 77 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Vertex Pharmaceuticals Incorporated Biotechnology VRTX$528.90 76 Health 76 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Watch WatchWorth tracking, but timing is mixed — not a clear setup yet.
- Harmony Biosciences Holdings, Inc. Biotechnology HRMY$42.07 76 Health 76 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- BioMarin Pharmaceutical Inc. Biotechnology BMRN$64.63 74 Health 74 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
FAQ
How Compound Radar scores and tracks ACADIA Pharmaceuticals Inc. (ACAD).